Podcast
Pharmacy Focus
Hosted by Pharmacy Times · EN
The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy. Winner of the 2021 Digital Health Media/Publications Audio Merit Award.
26episodes
Episodes
Newest firstAll episodes
S2 Ep78: Hepatitis B Vaccination in Adults: Overcoming Stigma and Improving Protection
1w ago00:27:48Tap to summarizeYou can connect with Marilyn Bulloch on LinkedIn here.Read more insights about hepatitis B throughout Hepatitis Awareness Month at Pharmacy Times' Hepatitis Resource Center.Episode Timestamps:1:05: Introduction2:08: Current Disease Burden of Hepatitis B3:55: Risk Landscape for Adults7:20: Link Between Chronic Hepatitis B and Liver Cancer10:25: Expanded Vaccine Recommendations13:25: The Role of Pharmacists in Vaccine Counseling16:40: Why Shorter Conversations Are Better17:55: Advantages of 2-Dose Schedule20:40: Closing the Adult Hepatitis B Immunization Gap23:50: A Patient Counseling Scenario25:25: Closing Thoughts
Transcribe →
S2 Ep77: "I've Been Doing Some Research": Wellness, Mistrust, and the Space Between
2w ago00:47:16Tap to summarizeWhen a cancer patient says "I've been doing some research," the conversation that follows can be just as complex as the treatment itself. In this episode, a malignant hematology clinical pharmacy specialist joins us to unpack health misinformation, AI-generated medical advice, wellness culture, and the controversial therapies oncology patients are bringing into the clinic — and how pharmacists can navigate it all.
Transcribe →
S2 Ep75: Recapping the AAN 2026 Annual Meeting: Neurologic Disease Treatment Is Rapidly Evolving
2w ago01:07:29Tap to summarizeThis inaugural episode of Mind the Meds introduces neurology pharmacy practice through a discussion between 3 neurology pharmacists working across inpatient and outpatient settings at the University of Utah. Host Erica Marini, PharmD, meets with her colleagues, Sarah Dahoney, PharmD, and Tyler Kenny, PharmD, BCCCP, both of whom are clinical pharmacists at the University of Utah Health, to discuss the research presented at the 2026 American Academy of Neurology (AAN) Annual Meeting. After sharing their diverse professional “origin stories,” the conversation then shifts to the role of pharmacists in neurology care and highlights key updates from the American Academy of Neurology annual meeting. The hosts discuss advances in neuromuscular disease, particularly myasthenia gravis, where emerging therapies such as FcRn inhibitors and CAR T-cell therapies are reshaping treatment paradigms. They also explore rare neurological conditions like stiff person syndrome and Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), where early-phase trials suggest promising but still preliminary therapeutic options. Finally, the episode reviews broader neurologic and systemic trends, including GLP-1 receptor agonists and SGLT2 inhibitors, noting potential but not yet definitive benefits in dementia prevention, stroke risk reduction, and migraine outcomes. Across all topics, the episode emphasizes the rapid evolution of neurological therapeutics and the expanding role of pharmacists in maneuvering complex, high-cost, and highly specialized treatments.Key Takeaways: Neurology pharmacy is highly collaborative and evolving, with non-linear career pathways. Pharmacists in neurology often enter the field through diverse experiences rather than a standardized training pipeline, and success depends heavily on adaptability, clinical curiosity, and initiative. Pharmacists play a critical role in optimizing complex neurological therapies and care transitions. Their contributions span inpatient safety monitoring, outpatient medication access and affordability support, and ensuring continuity of care for high-risk, high-cost therapies. Neurology therapeutics are rapidly advancing, but many emerging treatments remain early-stage. New therapies such as FcRn inhibitors, CAR T-cell approaches, and complement-targeting agents show promise across conditions like myasthenia gravis and rare neuroimmunologic diseases, while broader drug classes like GLP-1s are still under investigation for neurological benefits.
Transcribe →S2 Ep74: Sacituzumab Govitecan and the New Standard of Care- What the NCCN Update Means for First-Line Metastatic TNBC
3w ago00:20:15Tap to summarizeNo description available
Transcribe →S2 Ep73: Introducing the Mind the Meds Podcast
4w ago00:05:04Tap to summarizeNo description available
Transcribe →S2 Ep72: APhA Preview - Dr. JAM Highlights Strategies for RSV Prevention in Adults
Mar 2600:31:37Tap to summarizeDr. JAM can be found on LinkedIn.Stay tuned for Pharmacy Times' coverage of APhA 2026 in LA. It can all be found here.
Transcribe →S2 Ep71: From Global Insights to the Aisle: Practical OTC Allergy Tips for Pharmacists
Feb 1700:25:57Tap to summarizeYou can find more information about Derek Webb, PharmD, and Dennis Williams, PharmD, BCPS, AEC, below:Derek Webb on LinkedInDennis Williams on LinkedInDennis Williams Faculty Page - UNC Eshelman School of PharmacyThis content was independently developed by Pharmacy Times. While we acknowledge the support of our sponsor, all editorial decisions and opinions remain solely those of Pharmacy Times. Any reference to brands is for informational purposes only and not an endorsement.
Transcribe →S2 Ep70: Global Lessons From FIP: How Pharmacists Can Elevate OTC Allergy Care
Feb 1300:18:18Tap to summarizeYou can find more information about Derek Webb, PharmD, and Dennis Williams, PharmD, BCPS, AEC, below:Derek Webb on LinkedInDennis Williams on LinkedInDennis Williams Faculty Page - UNC Eshelman School of PharmacyThis content was independently developed by Pharmacy Times. While we acknowledge the support of our sponsor, all editorial decisions and opinions remain solely those of Pharmacy Times. Any reference to brands is for informational purposes only and not an endorsement.
Transcribe →S2 Ep69: Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
Feb 600:39:42Tap to summarizeNo description available
Transcribe →S2 Ep68: From Underdiagnosed to Under Control: Plozasiran and Pharmacists’ Role in FCS
Jan 3000:22:51Tap to summarizeOn Chen, MD, and Tahmid Rahman, MD discuss how plozasiran—an RNA-based APOC3-targeting therapy for patients with familial chylomicronemia syndrome with infrequent injections and a favorable safety profile—can transform care when integrated through coordinated multidisciplinary workflows with pharmacists leading patient identification, access, and monitoring.
Transcribe →